Edwards Lifesciences Receives FDA Approval for Its New Class of Heart Valves
Last week FDA approved Edwards Lifesciences Corp.’s Inspiris Resilia aortic valve, which the company is calling a new class of resilient heart valves. Intended for surgical aortic valve replacement, the device platform is built on the design of the Carpentier-Edwards Perimount valve, which has 20 years of clinical use behind it. The valve features tissue technology that combines anti-calcification properties, sustained hemodynamic performance and dry storage. Its VFit technology has an expandable frame and includes fluroscopically visible size markers and can be used in future valve-in-valve procedures.
The company plans to launch the valve in the United States early next year. It was launched in Europe earlier this year.
Related Articles
-
“We are honored to have Dr. Lace, who is widely recognized as one of the industry’s most trusted reimbursement experts, leading our new division. He will also support all our services as our CMO.”
-
“Approaches to Increasing Diversity in Clinical Research and Addressing Health Inequities” offers key recommendations for device manufacturers and developers on steps they can take to increase diversity in clinical research and address health equity.
-
Market research and forecasting help ensure that you are investing in a device or drug that is needed and will be well received. In this article, Sanobar Syed, Associate Director of Forecasting, Market Insights and Strategies, BeiGene, highlights strategies to…
-
AI not only improves data collection and analysis, it impacts which products are engaged in clinical trials, determines necessary medical criteria, helps design the trials and can even choose the best participating facilities. The result is, organizations that leverage AI…
